QQQ $ 480.84 $ -1.29 (-0.27 %)
DIA $ 391.56 $ -0.73 (-0.19 %)
SPY $ 544.47 $ -0.73 (-0.13 %)
TLT $ 93.96 $ 0.00 (0 %)
GLD $ 214.79 $ -3.38 (-1.55 %)
$ 0.034
-- x --
-- x --
-- - --
$ 0.02 - $ 0.74
3,429,331
na
na
$ 0.53
na
TBD
na
na (na)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 heat-biologics-nighthawk-biosciences-announces-that-its-elusys-therapeutics-subsidiary-has-executed-a-contract-to-deliver-anthim-to-the-canadian-government-for-c79m

Heat Biologics, Inc. (NYSE American: HTBX) (to be renamed "NightHawk Biosciences"), a fully integrated biopharmaceutica...

 heat-biologics-announces-planned-name-change-to-nighthawk-biosciences-will-trade-under-ticker-nhwk-effective-may-3-2022

Heat Biologics, Inc. ("Heat") (NYSE American: HTBX), a clinical-stage biopharmaceutical company focused on developing n...

 heat-biologics-announces-planned-investor-and-media-livestream-event-to-discuss-latest-developments-for-april-19

Heat Biologics, Inc. ("Heat") (NYSE American: HTBX), a clinical-stage biopharmaceutical company focused on developing f...

 heat-biologics-shares-spike-to-session-high-up-8-co-purchased-elusys-therapeutics-in-dec-2021-elusyss-anthim-was-approved-for-treatment-of-inhalation-of-anthrax-in-us-canada-europe-uk

https://ir.heatbio.com/press-releases/detail/706/heat-biologics-announces-planned-acquisition-of-elusys

 66-biggest-movers-from-yesterday
66 Biggest Movers From Yesterday
03/23/2022 08:25:32

Gainers JX Luxventure Limited (NASDAQ: LLL) shares jumped 119.5% to settle at $4.39 on Tuesday after the company announced i...

 b-riley-securities-maintains-buy-on-heat-biologics-lowers-price-target-to-8

B. Riley Securities analyst Mayank Mamtani maintains Heat Biologics (AMEX:HTBX) with a Buy and lowers the price target from ...

 heat-biologics-shares-tick-higher-on-volume-following-circulation-of-zacks-small-cap-research-note-showing-19-valuation-target-on-stock

https://s27.q4cdn.com/906368049/files/News/2022/Zacks_SCR_Reserach_03172022_HTBX_Vandermosten.pdf

 heat-biologicss-return-on-capital-employed-overview

Heat Biologics (NASDAQ:HTBX) brought in sales totaling $613.10 thousand during Q4 according to data provided by Benzinga Pro. H...

 stocks-that-hit-52-week-lows-on-tuesday

    Tuesday's session saw 729 companies set new 52-week lows.

 heat-biologics-says-co-elusys-therapeutics-waived-until-march-31-their-right-to-terminate-agreement-and-plan-of-merger-and-reorganization

-Reuters

 heat-biologics-merger-partner-elusys-finalizes-hhs-contract-for-its-anthrax-treatment

Elusys Therapeutics Inc, the merger partner for Heat Biologics Inc (NASDAQ: HTBX), has 

 heat-biologics-merger-partner-elusys-therapeutics-says-has-finalized-contract-with-hhs-office-of-the-assistant-secretary-for-preparedness-and-response-completed-first-phase-of-contract-for-50m

Completed first phase of contract for $50 million; HHS options to procure up to $31 million of ANTHIM by the first half of 2023...

 stocks-that-hit-52-week-lows-on-thursday

  During Thursday's morning trading, 152 companies set new 52-week lows.

 htbx-rapidvax-unveiled-elusys-acquisition

By John Vandermosten, CFA NASDAQ:HTBX READ THE FULL HTBX RESEARCH REPORT

 heat-biologics-shares-spiked-higher-midday-now-up-2-recent-zacks-small-cap-research-report-suggested-19-valuation-target-on-stock

https://s27.q4cdn.com/906368049/files/News/2022/Zacks_SCR_Research_01132022_HTBX_Vandermosten.pdf

 heat-biologics-issues-new-ptx-35-preclinical-data-in-organ-transplantation-update-on-hs-110

Heat Biologics Inc (NASDAQ: HTBX) announced 

 heat-biologics-announces-new-ptx-35-preclinical-data-in-organ-transplantation-and-provides-update-on-hs-110

A single dose of the preclinical version of PTX-35 (mPTX-35), was able to expand regulatory T cells (Tregs) and significantly...